Prospective Exploratory Evaluation of Cepheid Xpert Mycobacterium tuberculosis Host Response Cartridge: A Focus on Adolescents and Young Adults
Open Access
- 5 September 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (1) , 180-188
Abstract
Background: An accurate, rapid, non-sputum-based triage test for diagnosing tuberculosis (TB) is needed. Methods: A prospective evaluation of the Cepheid GeneXpert Mycobacterium tuberculosis Host Response cartridge (Xpert-MTB-HR), a prototype blood-based host response mRNA signature assay, among individuals presenting with TB-like symptoms was performed in Pakistan and results were compared to 3 reference standards: Xpert MTB/RIF Ultra, bacteriological confirmation (Xpert MTB/RIF Ultra and/or culture positivity), and composite clinical diagnosis (clinician diagnosis, treatment initiation, Xpert MTB/RIF Ultra, and/or culture positivity). Analyses were conducted both for the entire study cohort and separately in the adolescent and young adult cohort (aged 10–24 years). Results: A total of 497 participants, aged 6–83 years, returned valid Xpert-MTB-HR results. When a diagnostic threshold was set for a sensitivity of >90%, specificity was 32% (95% confidence interval [CI], 28%–37%) compared to Xpert MTB/RIF Ultra, 29% (95% CI, 25%–34%) compared to a bacteriological confirmation, and 22% (95% CI, 18%–26%) compared to a composite clinical diagnosis. However, when evaluating only the adolescent and young adult cohort with a diagnostic threshold set for sensitivity of >90%, specificity was 82% (95% CI, 74%–89%) compared to Xpert MTB/RIF Ultra, 84% (95% CI, 75%–90%) compared to a bacteriological confirmation, and 54% (95% CI, 44%–64%) compared to a composite clinical diagnosis. Conclusions: While the Xpert-MTB-HR does not meet World Health Organization minimum criteria in the general population, in our study it does meet the minimum sensitivity and specificity requirements for a non-sputum-based triage test among adolescents and young adults when compared to Xpert MTB/RIF Ultra or bacteriological confirmation.Keywords
Funding Information
- National Institutes of Health (T32AI007384)
- MTB
This publication has 21 references indexed in Scilit:
- Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South AfricaThe Lancet Global Health, 2024
- Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countriesThe Lancet Infectious Diseases, 2023
- Caring for Adolescents and Young Adults With Tuberculosis or at Risk of Tuberculosis: Consensus Statement From an International Expert PanelJournal of Adolescent Health, 2023
- Adolescent tuberculosisThe Lancet Child & Adolescent Health, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment ResponseJAMA Network Open, 2018
- The age of adolescenceThe Lancet Child & Adolescent Health, 2018
- Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysisThe Lancet Respiratory Medicine, 2016
- Epidemiology of Sarcoidosis 1946-2013Mayo Clinic Proceedings, 2016
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009